Research and Markets has announced the addition of the "Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Pipeline Review, H2 2016" report to their offering.

The report provides comprehensive information on the Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics development and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Alpha 2C Adrenergic Receptor Overview
  3. Therapeutics Development
  4. Pipeline Products for Alpha 2C Adrenergic Receptor - Overview
  5. Pipeline Products for Alpha 2C Adrenergic Receptor - Comparative Analysis
  6. Alpha 2C Adrenergic Receptor - Therapeutics under Development by Companies
  7. Alpha 2C Adrenergic Receptor - Therapeutics under Investigation by Universities/Institutes
  8. Alpha 2C Adrenergic Receptor Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Alpha 2C Adrenergic Receptor - Products under Development by Companies
  13. Alpha 2C Adrenergic Receptor - Products under Investigation by Universities/Institutes
  14. Alpha 2C Adrenergic Receptor - Companies Involved in Therapeutics Development
  • Egis Gyogyszergyar Nyrt
  • Johnson & Johnson
  • Otsuka Holdings Co Ltd
  • SK Biopharmaceuticals Co Ltd
  • TearSolutions LLC

For more information about this report visit http://www.researchandmarkets.com/research/qx428c/alpha_2c